Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery

BACKGROUND: The ability to analyze the genomics of malignancies has opened up new possibilities for off-label targeted therapy in cancers that are refractory to standard therapy. At Mayo Clinic these efforts are organized through the Center for Individualized Medicine (CIM). RESULTS: Prior to GTB, d...

Descripción completa

Detalles Bibliográficos
Autores principales: Bryce, Alan H., Egan, Jan B., Borad, Mitesh J., Stewart, A. Keith, Nowakowski, Grzegorz S., Chanan-Khan, Asher, Patnaik, Mrinal M., Ansell, Stephen M., Banck, Michaela S., Robinson, Steven I., Mansfield, Aaron S., Klee, Eric W., Oliver, Gavin R., McCormick, Jennifer B., Huneke, Norine E., Tagtow, Colleen M., Jenkins, Robert B., Rumilla, Kandelaria M., Kerr, Sarah E., Kocher, Jean-Pierre A., Beck, Scott A., Fernandez-Zapico, Martin E., Farrugia, Gianrico, Lazaridis, Konstantinos N., McWilliams, Robert R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432324/
https://www.ncbi.nlm.nih.gov/pubmed/28423702
http://dx.doi.org/10.18632/oncotarget.16057

Ejemplares similares

Ejemplares similares